| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 136, 1978-1986, Copyright © 1995 by Endocrine Society
ARTICLES |
WJ Langlois, T Sasaoka, CC Yip and JM Olefsky
Department of Medicine, University of California, San Diego, La Jolla 92093, USA.
To assess the characteristics of hybrid receptors composed of one kinase-inactive alpha beta-insulin half-receptor and one endogenous alpha beta-insulin-like growth factor 1 (IGF-1) or insulin half- receptor, a cell line expressing an insulin receptor truncated by 365 amino acids (HIR delta 978) was studied, which lacks most of the cytoplasmic beta-subunit. Analysis by sodium dodecyl sulfate polyacrylamide gel electrophoresis under nonreducing conditions revealed four distinct receptor species: endogenous receptors, the more rapidly migrating HIR delta 978 homodimer, and two intermediate species representing HIR delta 978/IGF-1 hybrid receptors and HIR delta 978/IR hybrid receptors. In vivo ligand-binding affinity of the hybrid receptors was studied by receptor-ligand cross-linking, and the delta 978/IGF-1R hybrid receptor was found to have a high affinity for IGF-1, whereas its affinity for insulin was low. Autophosphorylation studies of lectin-purified receptors revealed that neither the HIR delta 978 holoreceptor nor the hybrid receptors underwent autophosphorylation in response to either ligand, despite the presence of intact IGF-1 or insulin half-receptors in the hybrids. Neither hybrid receptor underwent ligand-induced endocytosis, as assessed with the bioactive photoaffinity probes B2(2-nitro-4-azidophenylacetyl)-des-PheB1-insulin and N-epsilon B28-monoazidobenzoyl-IGF-1. In conclusion, the HIR delta 978/IGF-1R hybrid receptor has a high in vivo affinity for IGF-1 but not for insulin. Neither the delta 978/IGF-1R nor the delta 978/IR hybrids undergo autophosphorylation or ligand-induced endocytosis in response to either ligand, indicating that intramolecular trans-, rather than cis-, signal transduction is important in mediating autophosphorylation and endocytosis.
This article has been cited by other articles:
![]() |
H. Zhang and D. Yee Is the type I insulin-like growth factor receptor a therapeutic target in endometrial cancer? Clin. Cancer Res., November 1, 2006; 12(21): 6323 - 6325. [Full Text] [PDF] |
||||
![]() |
G. Li, E. J. Barrett, H. Wang, W. Chai, and Z. Liu Insulin at Physiological Concentrations Selectively Activates Insulin But Not Insulin-Like Growth Factor I (IGF-I) or Insulin/IGF-I Hybrid Receptors in Endothelial Cells Endocrinology, November 1, 2005; 146(11): 4690 - 4696. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Yuen, J. Frystyk, M. Umpleby, L. Fryklund, and D. Dunger Changes in Free Rather Than Total Insulin-Like Growth Factor-I Enhance Insulin Sensitivity and Suppress Endogenous Peak Growth Hormone (GH) Release following Short-Term Low-Dose GH Administration in Young Healthy Adults J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3956 - 3964. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Kiely, A. Sant, and R. O'Connor RACK1 Is an Insulin-like Growth Factor 1 (IGF-1) Receptor-interacting Protein That Can Regulate IGF-1-mediated Akt Activation and Protection from Cell Death J. Biol. Chem., June 14, 2002; 277(25): 22581 - 22589. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Cusi and R. DeFronzo Recombinant Human Insulin-Like Growth Factor I Treatment for 1 Week Improves Metabolic Control in Type 2 Diabetes by Ameliorating Hepatic and Muscle Insulin Resistance J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3077 - 3084. [Abstract] [Full Text] |
||||
![]() |
S. Jain, D. W. Golde, R. Bailey, and M. E. Geffner Insulin-Like Growth Factor-I Resistance Endocr. Rev., October 1, 1998; 19(5): 625 - 646. [Abstract] [Full Text] |
||||
![]() |
M. Federici, O. Porzio, D. Lauro, P. Borboni, B. Giovannone, L. Zucaro, M. L. Hribal, and G. Sesti Increased Abundance of Insulin/Insulin-Like Growth Factor-I Hybrid Receptors in Skeletal Muscle of Obese Subjects Is Correlated with In Vivo Insulin Sensitivity J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2911 - 2915. [Abstract] [Full Text] |
||||
![]() |
F. L. Garrouste, M. M. Remacle-Bonnet, M. M.-A. Lehmann, J. L. Marvaldi, and G. J. Pommier Up-Regulation of Insulin/Insulin-Like Growth Factor-I Hybrid Receptors during Differentiation of HT29-D4 Human Colonic Carcinoma Cells Endocrinology, May 1, 1997; 138(5): 2021 - 2032. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Li, M. Resnicoff, and R. Baserga Effect of Mutations at Serines 1280-1283 on the Mitogenic and Transforming Activities of the Insulin-like Growth Factor I Receptor J. Biol. Chem., May 24, 1996; 271(21): 12254 - 12260. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |